{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:30:38Z","timestamp":1790677838341,"version":"4.1.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T00:00:00Z","timestamp":1580342400000},"content-version":"am","delay-in-days":394,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue des Maladies Respiratoires"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.rmr.2018.04.010","type":"journal-article","created":{"date-parts":[[2019,1,10]],"date-time":"2019-01-10T17:17:34Z","timestamp":1547140654000},"page":"104-117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Place des nouveaux antibiotiques dans le traitement de la pneumonie aigu\u00eb communautaire de l\u2019adulte"],"prefix":"10.1016","volume":"36","author":[{"given":"L.","family":"Bondeelle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bergeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmr.2018.04.010_bib0005","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1136\/thx.46.7.508","article-title":"Aetiology of community acquired pneumonia in Valencia Spain: a multicentre prospective study","volume":"46","author":"Blanquer","year":"1991","journal-title":"Thoraxl"},{"key":"10.1016\/j.rmr.2018.04.010_bib0010","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1164\/ajrccm\/148.5.1418","article-title":"Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association","volume":"148","author":"Niederman","year":"1993","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.rmr.2018.04.010_bib0015","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200405-644ST","article-title":"Guidelines for the management of adults with hospital-acquired, ventilator-associated and healthcare-associated pneumonia","volume":"171","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2018.04.010_bib0020","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S1473-3099(10)70032-3","article-title":"Rethinking the concepts of community-acquired and health-care-associated pneumonia","volume":"10","author":"Ewig","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.rmr.2018.04.010_bib0025","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1164\/ajrccm.163.3.2005075","article-title":"Etiology of severe pneumonia in the very elderly","volume":"163","author":"El-Solh","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2018.04.010_bib0030","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1164\/rccm.200202-123OC","article-title":"Impact of invasive strategy on management of antimicrobial treatment failure in institutionalized older people with severe pneumonia","volume":"166","author":"El-Solh","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2018.04.010_bib0035","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1500245","article-title":"Community-acquired pneumonia requiring hospitalization among U.S adults","volume":"373","author":"Jain","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2018.04.010_bib0040","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/jama.2016.0115","article-title":"Antibiotic therapy for adults hospitalized with community-acquired pneumonia: a systematic review","volume":"315","author":"Lee","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.rmr.2018.04.010_bib0045","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0140-6736(15)60733-4","article-title":"Community-acquired pneumonia","volume":"386","author":"Prina","year":"2015","journal-title":"Lancet Lond Engl"},{"issue":"1","key":"10.1016\/j.rmr.2018.04.010_bib0050","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10096-016-2779-5","article-title":"Improved survival among ICU-hospitalized patients with community-acquired pneumonia by unidentified organisms: a multicenter case-control study","volume":"36","author":"Rello","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.rmr.2018.04.010_bib0055","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1056\/NEJM199701233360402","article-title":"A prediction rule to identify low-risk patients with community-acquired pneumonia","volume":"336","author":"Fine","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2018.04.010_bib0060","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1136\/thx.56.suppl_4.iv1","article-title":"BTS guidelines for the management of community acquired pneumonia in adults","volume":"56","year":"2001","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2018.04.010_bib0065","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1378\/chest.125.6.2135","article-title":"Levofloxacin efficacy in the treatment of community-acquired legionellosis","volume":"125","author":"Yu","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2018.04.010_bib0070","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1471-2334-11-66","article-title":"Severe pneumococcal pneumonia: impact of new quinolones on prognosis","volume":"11","author":"Olive","year":"2011","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.rmr.2018.04.010_bib0075","series-title":"\u00c9tude Burden BMR\u00a0: estimation du poids des infections \u00e0 bact\u00e9ries multir\u00e9sistantes en France","year":"2017"},{"key":"10.1016\/j.rmr.2018.04.010_bib0080","series-title":"Premier rapport de l\u2019OMS sur la r\u00e9sistance aux antibiotiques\u00a0: une menace grave d\u2019ampleur mondiale","author":"OMS","year":"2014"},{"key":"10.1016\/j.rmr.2018.04.010_bib0085","series-title":"Antimicrobial resistance in Europe: http:\/\/antimicrobial-resistance-europe-2015.pdf","year":"2015"},{"key":"10.1016\/j.rmr.2018.04.010_bib0090","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s12879-015-0978-9","article-title":"Trends in antibiotic resistance of Streptococcus pneumoniae and Haemophilus influenzae isolated from nasopharyngeal flora in children with acute otitis media in France before and after 13\u00a0valent pneumococcal conjugate vaccine introduction","volume":"15","author":"Angoulvant","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.rmr.2018.04.010_bib0095","doi-asserted-by":"crossref","first-page":"6178","DOI":"10.1016\/j.vaccine.2015.10.015","article-title":"Invasive disease potential of pneumococci before and after the 13-valent pneumococcal conjugate vaccine implementation in children","volume":"33","author":"Varon","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.rmr.2018.04.010_bib0100","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1093\/cid\/ciu006","article-title":"Early Impact of 13-valent pneumococcal conjugate vaccine on community \u2013 acquired pneumonia in children","volume":"58","author":"Angoulvant","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rmr.2018.04.010_bib0105","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3389\/fmicb.2016.00974","article-title":"Mycoplasma pneumoniae: current knowledge on macrolide resistance and treatment","volume":"7","author":"Pereyre","year":"2016","journal-title":"Front Microbiol"},{"key":"10.1016\/j.rmr.2018.04.010_bib0110","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/cid\/ciw300","article-title":"Staphylococcus aureus community-acquired pneumonia: prevalence clinical characteristics, and outcomes","volume":"63","author":"Self","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rmr.2018.04.010_bib0115","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.diagmicrobio.2015.06.007","article-title":"Distribution and antimicrobial susceptibility of bacteria from adults with community-acquired pneumonia or complicated skin and soft tissue infections in France: the nationwide French PREMIUM study","volume":"83","author":"Leprince","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.rmr.2018.04.010_bib0120","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1111\/j.1469-0691.2011.03484.x","article-title":"Low incidence of multidrug-resistant organisms in patients with healthcare-associated pneumonia requiring hospitalization","volume":"17","author":"Garcia-Vidal","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.rmr.2018.04.010_bib0125","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/cid\/cir274","article-title":"Epidemiology, antibiotic therapy, and clinical outcomes in health care-associated pneumonia: a UK cohort study","volume":"53","author":"Chalmers","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rmr.2018.04.010_bib0130","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1164\/rccm.200212-1543OC","article-title":"Microbiology of severe aspiration pneumonia in institutionalized elderly","volume":"167","author":"El-Solh","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2018.04.010_bib0135","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1093\/jac\/dkw136","article-title":"Ceftaroline fosamil versus ceftriaxone for the treatment of community-acquired pneumonia: individual patient data meta-analysis of randomized controlled trials","volume":"71","author":"Taboada","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.rmr.2018.04.010_bib0140","series-title":"Fiche avis nouveau m\u00e9dicament\u00a0: zinforo_synthese_ct12539.pdf","year":"2013"},{"key":"10.1016\/j.rmr.2018.04.010_bib0145","doi-asserted-by":"crossref","first-page":"5849","DOI":"10.1128\/AAC.02755-15","article-title":"Penetration of ceftaroline into the epithelial lining fluid of healthy adult subjects","volume":"60","author":"Riccobene","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2018.04.010_bib0150","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1128\/AAC.01707-13","article-title":"In vivo efficacy of ceftaroline fosamil in a methicillin-resistant panton-valentine leukocidin-producing Staphylococcus aureus rabbit pneumonia model","volume":"58","author":"Croisier-Bertin","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2018.04.010_bib0155","series-title":"MABELIO_SApub_CT13417: mabelio_sapub_ct13417.pdf","year":"2014"},{"key":"10.1016\/j.rmr.2018.04.010_bib0160","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2165\/11594090-000000000-00000","article-title":"Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents","volume":"50","author":"Rodvold","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.rmr.2018.04.010_bib0165","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s40262-016-0418-z","article-title":"Pharmacokinetics and dosing of ceftobiprole medocaril for the treatment of hospital and community-acquired pneumonia in different patient populations","volume":"55","author":"Torres","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.rmr.2018.04.010_bib0170","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1128\/AAC.00185-16","article-title":"Results from the Solithromycin International Surveillance Program (2014)","volume":"60","author":"Farrell","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2018.04.010_bib0175","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1128\/AAC.01639-13","article-title":"Antimicrobial activity of solithromycin against clinical isolates of Legionella pneumophila serogroup 1","volume":"58","author":"Mallegol","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2018.04.010_bib0180","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1473-3099(16)00017-7","article-title":"Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL)","volume":"16","author":"Barrera","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.rmr.2018.04.010_bib0185","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/cid\/ciw490","article-title":"SOLITAIRE-IV: a randomized, double-blind, multicenter study comparing the efficacy and safety of intravenous-to-oral solithromycin to intravenous-to-oral moxifloxacin for treatment of community-acquired bacterial pneumonia","volume":"63","author":"File","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.rmr.2018.04.010_bib0190","doi-asserted-by":"crossref","first-page":"875","DOI":"10.2146\/ajhp160934","article-title":"Solithromycin: a novel ketolide antibiotic","volume":"74","author":"Buege","year":"2017","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.rmr.2018.04.010_bib0195","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.2217\/fmb.15.39","article-title":"Delafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy","volume":"10","author":"Van Bambeke","year":"2015","journal-title":"Future Microbiol"},{"key":"10.1016\/j.rmr.2018.04.010_bib0200","series-title":"Study to compare delafloxacin to moxifloxacin for the treatment of adults with community-acquired bacterial pneumonia","year":"2016"},{"key":"10.1016\/j.rmr.2018.04.010_bib0205","series-title":"Omadacycline vs moxifloxacin for the treatment of CABP (EudraCT #2013-004071-13)","year":"2015"},{"key":"10.1016\/j.rmr.2018.04.010_bib0210","doi-asserted-by":"crossref","first-page":"iii19","DOI":"10.1093\/jac\/dkr096","article-title":"Focus 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"File","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.rmr.2018.04.010_bib0215","doi-asserted-by":"crossref","first-page":"iii33","DOI":"10.1093\/jac\/dkr097","article-title":"Focus 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"Low","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.rmr.2018.04.010_bib0220","first-page":"34","article-title":"Peut-on traiter les patients, avec comorbidit\u00e9s, hospitalis\u00e9s pour pneumonies communautaires par 3jours de b\u00e9talactamines\u00a0?","author":"Dinh","year":"2017","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.rmr.2018.04.010_bib0225","doi-asserted-by":"crossref","first-page":"20s","DOI":"10.1183\/09031936.02.00702002","article-title":"Community-acquired pneumonia in Europe: causative pathogens and resistance patterns","volume":"36","author":"Woodhead","year":"2002","journal-title":"Eur Respir J Suppl"},{"issue":"3","key":"10.1016\/j.rmr.2018.04.010_bib0230","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1097\/MJT.0000000000000551","article-title":"Antimicrobial resistant Streptococcus pneumoniae: prevalence, mechanisms, and clinical implications","volume":"24","author":"Cherazard","year":"2017","journal-title":"Am J Ther"},{"key":"10.1016\/j.rmr.2018.04.010_bib0235","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1128\/AAC.48.8.3016-3023.2004","article-title":"Emergence of Streptococcus pneumoniae with very-high-level resistance to penicillin","volume":"48","author":"Schrag","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2018.04.010_bib0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijantimicag.2008.12.012","article-title":"Ceftobiprole: a novel cephalosporin with activity against gram-positive and gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA)","volume":"34","author":"Barbour","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.rmr.2018.04.010_bib0245","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1128\/JCM.01892-09","article-title":"Prompt and successful toxin-targeting treatment of three patients with necrotizing pneumonia due to Staphylococcus aureus strains carrying the panton-valentine leukocidin genes","volume":"48","author":"Rouzic","year":"2010","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.rmr.2018.04.010_bib0250","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S1473-3099(09)70133-1","article-title":"Emergence of community-acquired meticillin-resistant Staphylococcus aureus strain USA 300\u00a0as a cause of necrotising community-onset pneumonia","volume":"9","author":"Hidron","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.rmr.2018.04.010_bib0255","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S2213-2600(14)70019-0","article-title":"Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Uzun","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2018.04.010_bib0260","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMoa1104623","article-title":"Azithromycin for prevention of exacerbations of COPD","volume":"365","author":"Albert","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2018.04.010_bib0265","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1124\/jpet.112.200733","article-title":"A novel macrolide solithromycin exerts superior anti-inflammatory effect via NF-\u03baB inhibition","volume":"345","author":"Kobayashi","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.rmr.2018.04.010_bib0270","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2165\/00002018-200831070-00002","article-title":"Benefit-risk assessment of telithromycin in the treatment of community-acquired pneumonia","volume":"31","author":"Brown","year":"2008","journal-title":"Drug Saf"},{"key":"10.1016\/j.rmr.2018.04.010_bib0275","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/jac\/dkw428","article-title":"Solithromycin, a novel macrolide, does not prolong cardiac repolarization: a randomized, three-way crossover study in healthy subjects","volume":"72","author":"Darpo","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.rmr.2018.04.010_bib0280","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/cid\/civ1214","article-title":"Comprehensive molecular testing for respiratory pathogens in community-acquired pneumonia","volume":"62","author":"Gadsby","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rmr.2018.04.010_bib0285","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jinf.2013.03.003","article-title":"Can an etiologic agent be identified in adults who are hospitalized for community-acquired pneumonia: results of a one-year study","volume":"67","author":"Musher","year":"2013","journal-title":"J Infect"},{"key":"10.1016\/j.rmr.2018.04.010_bib0290","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa1500245","article-title":"Community-acquired pneumonia requiring hospitalization","volume":"373","author":"Jain","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2018.04.010_bib0295","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.arbres.2010.06.014","article-title":"Neumon\u00eda adquirida en la comunidad. Nueva normativa de la Sociedad Espa\u00f1ola de Neumolog\u00eda y Cirug\u00eda Tor\u00e1cica (SEPAR)","volume":"46","author":"Men\u00e9ndez","year":"2010","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.rmr.2018.04.010_bib0300","series-title":"MAP\/antibioth\u00e9rapie par voie g\u00e9n\u00e9rale dans les infections respiratoires basses de l\u2019adulte\u00a0: 2010-infVRB-spilf-afssaps.pdf","year":"2010"},{"key":"10.1016\/j.rmr.2018.04.010_bib0305","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"Mandell","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 6","key":"10.1016\/j.rmr.2018.04.010_bib0310","article-title":"Clinical Microbiology and Infection. Guidelines for the management of adult lower respiratory tract infections","volume":"17","author":"Woodhead","year":"2011","journal-title":"Infect Dis"},{"key":"10.1016\/j.rmr.2018.04.010_bib0315","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.arbres.2010.06.014","article-title":"Community-acquired pneumonia. New Guidelines of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR)","volume":"46","author":"Men\u00e9ndez","year":"2010","journal-title":"Arch Bronconeumol Engl Ed"},{"key":"10.1016\/j.rmr.2018.04.010_bib0320","series-title":"ZERBAXA_SYNTHESE_CT14850: zerbaxa_synthese_ct14850_2016-11-03_10-53-24_290.pdf","year":"2016"},{"key":"10.1016\/j.rmr.2018.04.010_bib0325","series-title":"ZAVICEFTA_SYNTHESE_CT15531: zavicefta_synthese_ct15531.pdf","year":"2017"}],"container-title":["Revue des Maladies Respiratoires"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842518309732?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842518309732?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:18:09Z","timestamp":1760105889000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0761842518309732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0761842518309732"],"URL":"https:\/\/doi.org\/10.1016\/j.rmr.2018.04.010","relation":{},"ISSN":["0761-8425"],"issn-type":[{"value":"0761-8425","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Place des nouveaux antibiotiques dans le traitement de la pneumonie aigu\u00eb communautaire de l\u2019adulte","name":"articletitle","label":"Article Title"},{"value":"Revue des Maladies Respiratoires","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmr.2018.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Masson SAS on behalf of SPLF.","name":"copyright","label":"Copyright"}]}}